Immunitas Therapeutics

Immunitas is a therapeutics company based on single-cell genomics, focusing on advancing multiple programs to the clinic in immunology. Immunitas’ programs are derived from their platform, a cross-functional, highly integrated single-cell genomics approach that enables rapid target identification and validation while facilitating antibody discovery and engineering. IMT-009, a first-in-class NK and T cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematologic malignancies. Immunitas is also advancing IMT-073, a dual-targeting NK and T cell modulator. The company was co-founded by Longwood Fund and leading scientists from Dana-Farber, MGH, Broad, and MIT.